Omeros (STU:3O8) Tariff Resilience Score: 6/10 (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3O8 Omeros Corp STU:3O8
33 GF Score
Price €16.50
! 6 Warning Signs
View Full Analysis

What is Omeros Tariff Resilience Score?

Omeros STU:3O8 +3.13% 33 Tariff Resilience Score is 6 as of Aug. 22, 2026. GuruFocus rates STU:3O8 with a GF Score™ of 33/100. The stock has 6 warning signs investors should review. Among 1,362 Biotechnology companies, Omeros ranks better than 76.06% on this metric.

Omeros has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Omeros has Omeros, a biopharmaceutical company, faces moderate tariff exposure due to its global supply chain for drug components. However, its primary market is domestic, and it has some pricing power. Past tariff changes have had limited impact on its operations.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Omeros might have Average Resilient.

Omeros  (STU:3O8) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Omeros Tariff Resilience Score Related Terms

STU:3O8 vs STTK, BBOT, XOMA: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Omeros's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Omeros Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Omeros's Tariff Resilience Score falls into.


STU:3O8
33GF Score
Omeros Corp STU:3O8
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Omeros (STU:3O8) has a Tariff Resilience Score of 6 as of Aug. 22, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Omeros ranks #326 out of 1362 companies in the Biotechnology industry, placing it in the top 23.9%.
Is Omeros' Tariff Resilience Score too high?
Omeros' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Omeros' value of 6 is 50% above this industry median. Based on the distribution chart, Omeros ranks #326 out of 1362 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Omeros has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Omeros' Tariff Resilience Score compare to STTK and BBOT?
According to the Biotechnology industry distribution chart, Omeros ranks #326 out of 1362 companies for Tariff Resilience Score. This places Omeros in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Omeros' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,362 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Omeros's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omeros's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omeros stock overvalued right now?
Omeros (STU:3O8) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Omeros' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Omeros (STU:3O8), the current Tariff Resilience Score is 6 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Omeros Business Description

Other Exchanges OMER:USA0KBU:UK
Address 201 Elliott Avenue West, Seattle, WA, USA, 98119
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
33GF Score

Get the complete analysis for STU:3O8

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.50
Price